shutterstock_2075328976_jhvephoto
JHVEphoto / Shutterstock.com
7 December 2021GenericsAlex Baldwin

Galderma sues Lupin over Oracea generic

Galderma Laboratories has sued Lupin Pharmaceuticals alleging that it plans to manufacture and sell a generic version of Oracea (doxycycline) prior to the expiration of key patents.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
30 January 2020   The US Court of Appeals for the Federal Circuit has revived patent infringement litigation brought against Teva by dermatological company Galderma, a former subsidiary of Nestlé Skin Health.
Americas
17 February 2016   Galderma Laboratories has successfully avoided three inter partes review petitions being instituted against a patent covering its Oracea (doxycycline, USP) drug, used to treat skin condition rosacea.
Generics
10 February 2022   Sun Pharmaceuticals and Lupin Pharmaceuticals have decided to settle a patent suit related to Sun’s Bromsite eye drops, invalidating an opinion handed down by the US District Court for the District of New Jersey in September.

More on this story

Americas
30 January 2020   The US Court of Appeals for the Federal Circuit has revived patent infringement litigation brought against Teva by dermatological company Galderma, a former subsidiary of Nestlé Skin Health.
Americas
17 February 2016   Galderma Laboratories has successfully avoided three inter partes review petitions being instituted against a patent covering its Oracea (doxycycline, USP) drug, used to treat skin condition rosacea.
Generics
10 February 2022   Sun Pharmaceuticals and Lupin Pharmaceuticals have decided to settle a patent suit related to Sun’s Bromsite eye drops, invalidating an opinion handed down by the US District Court for the District of New Jersey in September.

More on this story

Americas
30 January 2020   The US Court of Appeals for the Federal Circuit has revived patent infringement litigation brought against Teva by dermatological company Galderma, a former subsidiary of Nestlé Skin Health.
Americas
17 February 2016   Galderma Laboratories has successfully avoided three inter partes review petitions being instituted against a patent covering its Oracea (doxycycline, USP) drug, used to treat skin condition rosacea.
Generics
10 February 2022   Sun Pharmaceuticals and Lupin Pharmaceuticals have decided to settle a patent suit related to Sun’s Bromsite eye drops, invalidating an opinion handed down by the US District Court for the District of New Jersey in September.